WASHINGTON — On Friday, the acting FDA commissioner asked for an inquiry into extremely unusual connections between some of her agency’s drug reviewers and the developer of a contentious new Alzheimer’s drugs. Dr. Janet Woodcock made the unexpected announcement on Twitter. It’s the latest repercussion of the FDA’s approval of Aduhelm, a costly and untested […]
Read More